”We have Novo Nordisk; that’s a Picasso. We have Genmab; that’s a Monet”
Danish investor Florian Schönharting and a number of venture capitalists all agree that the Nordic biotech sector is certainly not heading for a bubble, and that some companies are actually underrated.
BY STEFAN SINGH KAILAY
Why the heck are the Danish-based pensions groups not investing in the biotech sector? Are we headed for a bubble in the Nordic countries? And why do we not see any biotech IPOs in Denmark?
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Nordea sees increasing tailwind for Genmab
For abonnenter
Biotech investor sets his sights on fibrosis
For abonnenter
More Danish life science acquisitions on the way
For abonnenter
